ESMO 2022: Neoadjuvant Pembrolizumab Safe, Effective Strategy for High-Risk Melanoma
At nearly 15 months, neoadjuvant pembrolizumab tied to improved event-free survival versus adjuvant treatment only
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.